100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 452
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Terrie J. Curran | President, CEO & Director | 1,22M | N/A | 1969 |
Mr. David A. Socks | Co-Founder & Director | 54,17k | N/A | 1975 |
Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & COO | 888,9k | N/A | 1960 |
Ms. Molly Henderson CPA, MBA | Chief Financial & Business Officer | 777,76k | N/A | 1971 |
Dr. Aditya Kohli Ph.D. | Co-Founder | 319,65k | N/A | 1989 |
Mr. Tom Harris | Chief Development Sciences Officer | N/A | N/A | N/A |
Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. Martin J. Gilligan | Chief Commercial Officer | N/A | N/A | N/A |
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.